Patent ID: 7405208

Claim:
A method for treatment of breast cancer or lung cancer in a subject suffering therefrom, comprising the steps of: (a) administering to said subject a substantially sub-toxic dose of an Hsp90 client protein inhibitor, wherein the Hsp90 client protein inhibitor is N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl(propoxy]-4-quinazolinamine (Iressa); (b) waiting a period of time sufficient to allow development of a substantially efficacious response; and (c) administering to said subject a synergistic dose of a benzoquinone ansamycin, wherein the benzoquinone ansamycin is 17-allylamino-17-desmethoxy-geldanamycin (17-AAG) or 17-(2-dimethylamino)ethylamino-17-desmethoxygeldanamycin (17-DMAG).